BC2001, the largest randomised trial of bladder-sparing treatment for muscle-invasive bladder cancer, demonstrated improvement of local control and bladder cancer–specific survival from the addition of concomitant 5-fluorouracil and mitomycin C to radiotherapy.
This work explores the potential of spatial omics to improve our understanding of the underlying biology of urological cancers, with the aim of improving prediction,…
Treatment intensification strategies are reshaping the treatment landscape of metastatic castration-resistant prostate cancer. Genomic, molecular, and clinical indicators should be used to identify the optimal…
First-line treatment for metastatic renal cell carcinoma combines an anti-PD1 antibody with either an anti-CTLA4 antibody or an antiangiogenic tyrosine kinase inhibitor (TKI). Treatment selection…
The evidence in the field of diagnosis, staging, and treatment of localised prostate cancer (PCa) is evolving rapidly. The 2024 European Association of Urology (EAU)-European…
Stereotactic body radiotherapy (SBRT) without androgen deprivation therapy (ADT) has lower rates of incontinence and sexual dysfunction, with a small trade-off in bowel bother, compared…
Stereotactic body radiotherapy (SBRT) without androgen deprivation therapy (ADT) has lower rates of incontinence and sexual dysfunction, with a small trade-off in bowel bother, compared…
In a contemporary cohort of previously untreated patients with metastatic renal cell carcinoma, 8.1% had brain metastases. We found that intensive systemic and focal therapies…
Patients with non–muscle-invasive bladder cancer (NMIBC) are at high risk of recurrence and progression. The rates for these events are impacted by clinical and pathological…
This overview of the 2024 European Association of Urology guidelines offers valuable insights into risk factors, diagnosis, classification, prognostic factors, treatment, and follow-up of non–muscle-invasive…
Emmett L, Subramaniam S, Crumbaker M, et al
